Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and ...
205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligible Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a …